Seres Therapeutics Inc (NASDAQ:MCRB) Reports Q2 2025 Earnings: Narrower EPS Loss but Shares Dip in Pre-Market Seres Therapeutics reports Q2 2025 results with $0.0 revenue and a narrower EPS loss of $2.27, beating estimates. Shares dip 4.5% pre-market despite recent 23% gain. Progress noted in SER-155 clinical trials.
Stay updated with the stocks that are on the move in today's pre-market session. Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Stay updated with the stocks that are on the move in today's after-hours session. As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
What's going on in today's after hours session Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024 MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
